Clinical trials: Antimicrobial
Pulmonary Infections, Pseudomonas Aeruginosa
Second Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were…
- Trial name
- NCT01069705
- Testing
- Tobramycin inhalation powder
- Where
- 17 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Gram-negative Bacterial Infection
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
This study will assess the pharmacokinetics, safety, and tolerability of single and multiple doses of intravenous ceftazidime-avibactam in hospitalized infants and neonates from 26 weeks gestation to 3 months of age.
- Trial name
- NOOR (NCT04126031)
- Testing
- Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
- Where
- 18 sites in United States, Estonia and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Chronic Rhinosinusitis (CRS), Exacerbations
Effect of Pleuran on the Clinical Course of Patients With Chronic Rhinosinusitis
The goal of this clinical research is to learn if Imunoglukan P4H® as an add-on therapy to the standard of care treatment according to the EPOS guidelines (intranasal corticosteroids and saline irrigation) can help to prevent CRS…
- Conditions
- Chronic Rhinosinusitis (CRS), Exacerbations, Respiratory Tract Infections (RTI), Antibiotic Prophylaxis
- Trial name
- EPCCOR (NCT07460934)
- Testing
- Imunoglukan P4H® capsules
- Where
- 5 sites in Czechia, Slovakia
- Volunteers
- 85 people
- Sponsor
- Pleuran, s.r.o.
Acne
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
- Trial name
- NCT00841776
- Testing
- Duac, Ziana gel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Stiefel, a GSK Company
Bacteremia, Fungemia
Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture
The "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification \& Antimicrobial Susceptibility Testing" is designed to validate the clinical performance of the Accelerate ID/AST…
- Trial name
- NCT02719769
- Where
- 14 sites in United States
- Volunteers
- 4,009 people
- Sponsor
- Accelerate Diagnostics, Inc.
Antibiotic-associated Diarrhea
Bacillus Particles Prevent Children Antibiotics Associated Diarrhea
This prospective, multicenter, randomized, double-blind, placebo-controlled clinical study, into the group of children in the hospital that use clinical antibiotics from one month to three years old，by observing the given…
- Trial name
- NCT02993419
- Testing
- Bacillus licheniformis Intervention
- Volunteers
- 480 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Nosocomial Infection
An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
The present study is a retrospective cohort study on patients who suffered a nosocomial infection in major hospitals in Vietnam.
- Trial name
- NCT00864929
- Where
- 2 sites in Vietnam
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Acne Vulgaris
A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash
The purpose of this study is to evaluate the tolerability of a combined regimen of a topical antibiotic and retinoid and a benzoyl peroxide wash.
- Trial name
- NCT00891982
- Testing
- CTGel/ BPO Wash, Soap Free Cleanser and CTGel
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Stiefel, a GSK Company
Cystic Fibrosis
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
The primary objective of this study is to evaluate the safety and efficacy of a CAT regimen with aztreonam for inhalation solution (AZLI) and tobramycin inhalation solution (TIS) in adult and pediatric subjects with cystic…
- Trial name
- AZLI CAT (NCT01641822)
- Testing
- AZLI, Tobramycin inhalation solution
- Where
- 71 sites in United States
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences
Drug Use
E-PAUse: Encouraging Proper Antibiotic Use in Outpatient Setting
Specific Aim 1: To determine the knowledge, attitude, and practice (KAP) of PHCC physicians regarding appropriate prescription of antibiotics in the outpatient setting.
- Trial name
- E-PAUse (NCT06135376)
- Testing
- comprehensive multi-component interventions
- Where
- Qatar
- Volunteers
- 100,000 people
- Sponsor
- Hamad Medical Corporation
Catheter-Related Infections
Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI
This is an Intermediate-Size Expanded Access, Open-Label Study for Use of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Central Line Associated Bloodstream Infection.
- Trial name
- MLK (NCT04513821)
- Testing
- Mino-Lok Therapy (MLT)
- Where
- 30 sites in United States, Puerto Rico
- Sponsor
- Leonard-Meron Biosciences, Inc.
Candidiasis, Oral, HIV Infections
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients…
- Trial name
- NCT00002431
- Testing
- Chlorhexidine gluconate
- Where
- 5 sites in United States
- Sponsor
- Procter and Gamble
Skin Infections, Bacterial
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
- Trial name
- NCT00133874
- Testing
- SB-275833 ointment, 1%
- Where
- 69 sites in Canada, Costa Rica and 8 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu.
- Trial name
- ZORO (NCT01231620)
- Testing
- Zanamivir, Oseltamivir
- Where
- 170 sites in United States, Australia and 26 more
- Volunteers
- 626 people
- Sponsor
- GlaxoSmithKline
Urinary Tract Infections
A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment…
- Trial name
- NCT07371429
- Testing
- Gepotidacin, SOC
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Gram Positive Bacterial Infection
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected…
- Trial name
- NCT01019395
- Testing
- Daptomycin
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF2 (NCT00104520)
- Testing
- AZLI 75 mg two times a day (BID)/three times a day (TID)
- Where
- 56 sites in United States
- Volunteers
- 211 people
- Sponsor
- Gilead Sciences
Infection
Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics
Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.
- Trial name
- NCT01311349
- Volunteers
- 1,575 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis
Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
The purpose of this study was to assess the pharmacokinetics, safety, and tolerability of a single intravenous dose of ceftolozane/tazobactam (MK-7625A) in pediatric participants.
- Trial name
- NCT02266706
- Testing
- Ceftolozane/Tazobactam 1000/500 mg, Ceftolozane/Tazobactam 30/15 mg/kg, Ceftolozane/Tazobactam 20/10 mg/kg
- Volunteers
- 43 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.
- Trial name
- EARLY (NCT01082367)
- Testing
- TOBI
- Where
- 19 sites in Canada, Egypt and 8 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals